In this update, we would like to highlight important studies currently enrolling at the research universities in our chapter, the University of Washington (UW) and Oregon Health & Science University (OHSU).

 

REMODEL T1D (RT1D) STUDY

In our last update, we shared that one area of focus in current Type 1 Diabetes (T1D) research is looking to see if drugs that have proven beneficial in Type 2 Diabetes (T2D) will have similar benefits for people with T1D.  The GLP-1 class of medications is one such area of focus, as we discussed in detail in our March Update.

GLP-1 agonists have been beneficial in T2D for their improvement of glycemic control and weight loss, as well as for their protective effects on the heart and kidney.

REMODEL T1D is looking at the potential benefits of the GLP-1 agonist, Semaglutide, on kidney function in people with abnormal kidney function due to T1D.  A secondary objective is to study the glycemic effects of Semaglutide in people with T1D.  This study is being conducted at UW in Seattle.

The study will last 26 weeks, including a gradual titration of study medications to maximum target dose over 12 weeks, followed by evaluation of the effect of Semaglutide on the kidney. Evaluation will include kidney MRI, urine testing and blood testing.

You may be eligible for this study if you:

• Are 18 years of age or older
• Have been diagnosed with T1D for at least 5 years
• Have abnormal kidney function due to T1D
• Are on stable doses of medications for blood pressure and cholesterol

If interested, please contact: Evelin Jones, evelinj@Nephrology.washington.edu  or Dori Khakpour, dorik@uw.edu

 

MULTI-SITE T1D CLOSED LOOP STUDY

This study is investigating a new investigational closed loop system, called iPancreas, which can detect exercise and missed meal boluses and adjust insulin dosing accordingly.  The system uses Fiasp insulin, a faster-acting version of Novolog.  The study is being conducted at OHSU, with an additional site at UW in Seattle.

During the course of the study, you will complete two visits. For one visit, you will use the study device with Fiasp insulin starting with a 6 hour visit on campus, followed by you using the system at home for 7 days. The other visit will require you to use your t:slim X2 pump with Control IQ with your own insulin for 7 days at home.

You may be eligible for this study if you:

• Are 18 years of age or older
• Have been using the t:slim X2 pump with Control IQ active for at least 12 weeks
• Have a HbA1c or GMI 7.5% or higher

If interested, please contact:  Deborah Branigan, oregonapc@ohsu.edu, 503-418-9070 for OHSU or Rosanna Holod, rambre@uw.edu or Dori Khakpour, dorik@uw.edu for UW.

 

DAILY DOSE SMART SNACK STUDY

OHSU also is testing a smart phone app, called Daily Dose.  By integrating with the Dexcom CGM, the app will predict overnight hypoglycemia and suggest an appropriate personalized bedtime snack.  The goal of this study is to test how well the Daily Dose app prevents nighttime hypoglycemia in people using multiple daily injections (MDIs).

Participation in the study will consist of 6 clinic and 6 phone visits over approximately 12 weeks. Some visits can be virtual.  During the study, you will be asked to wear a Dexcom G6 CGM (provided).  You also will be asked to wear an Apple watch (provided during the study period) at night and complete a survey about sleep quality each week.  You will weigh yourself weekly.  The snacks recommended by the Daily Dose app will be provided by the study.

You may be eligible for this study if you:

• Are 18 years of age or older
• Have been diagnosed with T1D for at least one year
• Are using multiple daily injection therapy
• Have an HbA1c <10% at time of screening
• Are currently using a glucose sensor with at least 2 episodes of overnight low glucose of less than 70 mg/dl for at least 10 minutes between 10pm and 6am in last 30 days

If interested, please contact:  Deborah Branigan, oregonapc@ohsu.edu, 503-418-9070.